Live GPS shows movement. Live heart rate shows response. Seeing both live changes decisions.

Demcon high-tech systems has been selected for Lot 4 in UKAEA’s Design & Build Framework, part of the Fusion Futures program. This selection follows our previous selections for Lot 2 and 3 within the new UKAEA Framework. This framework supports the development of future fusion technologies by engaging industry partners across design, engineering, prototyping and digital systems. This is now the third UKAEA framework in which Demcon participates, alongside the Engineering Design Services and Embedded Engineering Resource frameworks.

From 3 to 5 February 2026, we will exhibit at Binding Energy, the international conference on nuclear technologies in Aachen, Germany. This event brings together the fusion and fission communities to explore innovations in nuclear energy, including SMR deployment, tritium handling, and next-generation fusion power plant concepts. Later that month, from 25 to 27 February, we will also attend FusionX Global in Munich, Germany.

Curix, onderdeel van de Demcon group, werkt aan de ontwikkeling van baanbrekende technologie voor de behandeling van levensbedreigende en slopende hersenziekten. Deze nieuwe technologie maakt het mogelijk om de bloed-hersenbarrière tijdelijk te openen, waarmee een van de grootste uitdagingen binnen de neurologie wordt aangepakt. Hierdoor kunnen geneesmiddelen tegen hersentumoren en neurodegeneratieve aandoeningen, zoals de ziekte van Alzheimer en Parkinson, efficiënter worden toegediend. De deelname van Twinning Participaties stelt Curix in staat om een injectorsysteem te ontwikkelen dat geschikt is voor de eerste klinische studies in mensen. “Uiteindelijk willen we hiermee bijdragen aan verbeterde behandelingen van hersenziekten”, zegt Peter Frinking, managing director en chief scientific officer van Curix.

Curix, part of the Demcon group, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology. With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer's and Parkinson's disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix.